secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagonist Therapeutics, Inc (PTGX)
CIK:        0001377121
Form:       8-K
Filed at:   2023-07-05T23:59:59+00:00
Accession:  0001104659-23-077821
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protagonist: Ph2 REVIVE hits primary endpoint (p=0.0003); Ph3 VERIFY enrollment completion expected 1Q 2024
--------------------------------------------------------------------------------

- Phase 2b FRONTIER 1 trial of JNJ-2113 in moderate-to-severe psoriasis completed; Phase 3 psoriasis study initiation planned.
- Enrollment completion for Phase 3 VERIFY trial of rusfertide in polycythemia vera expected in 1Q 2024.
- Phase 2 REVIVE study met primary endpoint with high statistical significance (p=0.0003); 69.2% responders vs 18.5% placebo.
- Rusfertide showed rapid hematocrit control in PACIFIC study; safety profile generally well tolerated with no new signals.
- New Phase 2b study of JNJ-2113 in ulcerative colitis planned for 4Q 2023; cash runway through end of 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1377121/000110465923077821/0001104659-23-077821-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1377121/000110465923077821/tm2320477d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-077821

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer